Market open· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
LADENBURG, GERMANY - August 26, 2026 (NEWMEDIAWIRE) - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration...
All agenda items approved by a large majority 2026 Annual General Meeting elects Jack Yefei Ling as new member of the Supervisory Board LADENBURG, GERMANY - June 23, 2026 (NEWMEDIAWIRE) - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biote...
LADENBURG, GERMANY - April 6, 2026 (NEWMEDIAWIRE) - Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), will present promising preclinical data from its Amanitin-based ADC HDP-...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.